Sleep disturbance is a key behavioral risk factor for chronic medical conditions observed at high rates among overweight and obese individuals. Systemic inflammation, including that induced by stress, may serve as a common biological mechanism linking sleep, adiposity, and disease risk. To investigate these relationships, 48 postmenopausal women (mean age = 61.8) completed a standardized laboratory stress task during which time blood was collected at baseline and 30, 50 and 90+ min after stressor onset to assess circulating levels of interleukin (IL)-6, IL-10, and IL-6/IL-10 ratio. Self-reported global sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) while adiposity was estimated by body mass index. Sagittal diameter was obtained in clinic to estimate visceral abdominal adiposity. Multi-level growth curve models revealed that poorer self-reported sleep quality was associated with greater stressinduced increases in IL-6/IL-10 ratio. In terms of adiposity, higher sagittal diameter, but not BMI, was associated with greater IL-6 reactivity (p's < 0.05). Further, associations between sleep quality and cytokine reactivity varied as a function of sagittal diameter. Among poor sleepers (1 SD above mean of PSQI score), stress-induced increases in IL-6 and IL-6/IL-10 ratio were significantly steeper in those with high visceral adiposity (1 SD above the mean of sagittal diameter) compared to those with low visceral adiposity (1 SD below the mean of sagittal diameter). In sum, poorer sleep quality and greater visceral adiposity, separately and especially in combination, are associated with greater stress-related increases in systemic inflammation. This research may help elucidate the complex link between sleep, obesity and inflammatory disease risk.
Introduction
Sleep disturbance, characterized by short sleep duration and/or poor subjective sleep quality, is an important behavioral predictor of several physical health outcomes, including obesity (Gangwisch et al., 2005; Mozaffarian et al., 2011; Taheri et al., 2004) , cardiovascular disease (Gangwisch et al., 2006; Gottlieb et al., 2006; King et al., 2008; Unruh et al., 2008) , and type 2 diabetes (Cappuccio et al., 2010; Gangwisch et al., 2007) . While the specific pathways linking sleep and disease risk are unclear, emerging evidence suggests inflammatory processes may serve as key biological mechanisms.
Inflammation, mediated by elevations in pro-inflammatory proteins such as interleukin (IL)-6, is implicated in the pathogenesis of many of the diseases observed at high prevalence among poor sleepers (Libby, 2002; Pradhan et al., 2001; Ridker et al., 2000) . Recent studies show that short sleep duration and poor subjective sleep quality are associated with increased concentrations of IL-6 (Miller et al., 2009; Mullington et al., 2010; Suarez, 2008) . Elevated systemic levels of IL-6 have also been found among patients with clinical sleep disorders, such as primary insomnia (Burgos et al., 2006) . Further, several laboratory experiments, though not all (Born et al., 1997; Dimitrov et al., 2006; reviewed in Solarz et al., 2012) , demonstrate that sleep restriction of healthy sleepers results in elevations in plasma concentrations of IL-6 compared to a normal sleep condition (Shearer et al., 2001; Vgontzas et al., 1999 Vgontzas et al., , 2004 .
One pathway through which poor sleep may modulate inflammatory activity is via its impact on stress reactivity. An intriguing literature suggests that under conditions of sleep restriction individuals may be more reactive physiologically to stress. For instance, individuals deprived of a single night of sleep display
